UniSuper Management Pty Ltd Has $5.20 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

UniSuper Management Pty Ltd boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 38.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 7,306 shares of the biopharmaceutical company’s stock after acquiring an additional 2,013 shares during the period. UniSuper Management Pty Ltd’s holdings in Regeneron Pharmaceuticals were worth $5,204,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Sava Infond d.o.o. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $492,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in Regeneron Pharmaceuticals by 7.8% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 177,008 shares of the biopharmaceutical company’s stock valued at $127,118,000 after acquiring an additional 12,757 shares in the last quarter. Aviso Wealth Management lifted its position in shares of Regeneron Pharmaceuticals by 65.1% during the 4th quarter. Aviso Wealth Management now owns 2,674 shares of the biopharmaceutical company’s stock valued at $1,905,000 after acquiring an additional 1,054 shares during the period. Murphy & Mullick Capital Management Corp acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $316,000. Finally, Prestige Wealth Management Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 23.2% during the 4th quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 19 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of a number of analyst reports. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Bernstein Bank reduced their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. TD Cowen lowered their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, UBS Group cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $637.36 on Friday. The firm has a market cap of $69.68 billion, a PE ratio of 16.65, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 52 week low of $629.02 and a 52 week high of $1,211.20. The firm’s fifty day moving average is $683.88 and its 200-day moving average is $800.34. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business earned $11.86 EPS. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.